BiomX Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Research and development (“R&D”) expenses, net | 6,122 | 7,279 | 16,386 | 18,281 |
| General and administrative expenses | 2,414 | 3,248 | 7,339 | 8,756 |
| Goodwill impairment | - | 801 | - | 801 |
| Operating loss | 8,536 | 11,328 | 23,725 | 27,838 |
| Other expenses (income) | (24) | (84) | 52 | (2,189) |
| Interest expenses | 5 | 5 | 15 | 868 |
| Loss (income) from change in fair value of warrants | 730 | (20,559) | (1,682) | (24,417) |
| Finance expense (income), net | (84) | (332) | 746 | 1,104 |
| Loss (income) before tax | 9,163 | (9,642) | 22,856 | 3,204 |
| Tax expenses | 3 | - | 6 | 10 |
| Net loss (income) | 9,166 | (9,642) | 22,862 | 3,214 |
| Basic loss (earnings) per share of Common Stock | 0.29 | (0.31) | 0.80 | 0.32 |
| Diluted loss (earnings) per share of Common Stock | 0.29 | (0.31) | 0.80 | 2.45 |
| Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock | 31,399,552 | 16,366,122 | 28,653,244 | 9,944,266 |
| Weighted average number of shares used in computing diluted loss (earnings) per share of Common Stock | 31,399,552 | 16,387,633 | 28,653,244 | 11,294,880 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.